Cited by 241Pharmacogenetics and Drug MetabolismCoffee research and impactsGenetic Associations and Epidemiology

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

The interindividual differences in the 3‐demthylation of caffeine alias CYP1A2 is determined by both genetic and environmental factors

Rasmussen·2002·Pharmacogenetics

DOI 10.1097/00008571-200208000-00008

Open this paper in CoChat — free account

Abstract

This study investigated the role of genetic factors (CYP1A2) in caffeine metabolism. The CYP1A2 activity was determined in 378 Danish twins following oral intake of a single dose of 200 mg caffeine and subsequent determination of the caffeine ratio (AFMU+1MU+1MX)/17DMU in a 6-h urine sample. The mean (+/- SD) caffeine ratio was 5.9 +/- 3.4. The caffeine ratio was statistically significantly higher in men compared to women, in smoking men and women compared to non-smoking persons of the same gender and in women not taking oral contraceptives compared with women on oral contraceptives. Thus, we confirmed that CYP1A2 is more active in men than in women, that it is induced by smoking and inhibited by oral contraceptives. In the subsequent analysis of heritability, we included 49 monozygotic twin pairs and 34 same gender dizygotic twin pairs concordant for non-smoking and non-use of oral contraceptives. The intraclass correlation coefficient was 0.798 (95% confidence interval, 0.696-0.900) and 0.394 (95% confidence interval, 0.109-0.680) in the monozygotic and dizygotic twins, respectively. The correlation was statistically significantly higher (P = 0.0015) in the former compared with the latter. A biometrical model for the caffeine ratio including only additive genetic factors and unique environmental factors was the overall best fitting model. Estimates based on this model gave a heritability estimate of 0.725 (95% confidence interval 0.577-0.822). Unique environmental effects seem to account for the remainder 0.275 (95% confidence interval, 0.178-0.423). Our study shows that the CYP1A2 activity is mainly governed by genetic factors.

Integrity signals

Registry

Crossref · 10.1097/00008571-200208000-00008

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Factor Analysis and AIC
Akaike, H. (1987) · Psychometrika · doi:10.1007/bf02294359 · Cited by 5,264
POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MAN
Mahgoub, A., Dring, L. G., Idle, J. R., Lancaster, R., & Smith, R. L. (1977) · The Lancet · doi:10.1016/s0140-6736(77)91430-1 · Cited by 1,183
Functional significance of a C–>A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine
Sachse, C., Brockmöller, J., Bauer, S., & Roots, I. (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00898.x · Cited by 751
Potential Role of Pharmacogenomics in Reducing Adverse Drug Reactions
Phillips, K. A., Veenstra, D. L., Oren, E., Lee, J. K., & Sadée, W. (2001) · JAMA · doi:10.1001/jama.286.18.2270 · Cited by 705
A twin-pronged attack on complex traits
Martin, N. G., Boomsma, D. I., & Machin, G. A. (1997) · Nature Genetics · doi:10.1038/ng1297-387 · Cited by 654
Human cytochrome P-450PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines.
Butler, M. A., Iwasaki, M., Guengerich, F. P., & Kadlubar, F. F. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.20.7696 · Cited by 638
Defective N-oxidation of sparteine in man: A new pharmacogenetic defect
Eichelbaum, M. F., Spannbrucker, N., Steincke, B., & Dengler, H. J. (1979) · European Journal of Clinical Pharmacology · doi:10.1007/bf00562059 · Cited by 632
Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites
Butler, M. A., Lang, N. P., Young, J. F., Caporaso, N. E., Vineis, P., Hayes, R. B., Teitel, C. H., Massengill, J., Lawsen, M. F., & Kadlubar, F. F. (1992) · Pharmacogenetics · doi:10.1097/00008571-199206000-00003 · Cited by 419
Fluvoxamine is a potent inhibitor of cytochrome P4501A2
Brøsen, K., Skjelbo, E., Rasmussen, B. B., Poulsen, H. E., & Loft, S. H. (1993) · Biochemical Pharmacology · doi:10.1016/0006-2952(93)90272-x · Cited by 374
Pharmacogenetics of mephenytoin: A new drug hydroxylation polymorphism in man
K�pfer, A., & Preisig, R. (1984) · European Journal of Clinical Pharmacology · doi:10.1007/bf00541938 · Cited by 363

Show all 43 references

Research works printed but not linked: 4

Shimada, 1994, J Pharmacol Exp Ther, 270, 414
Shahidi, 1967, Am J Dis Child, 113, 81
Campbell, 1987, Drug Metab Dispos, 15, 237
Nakajima, 1994, Cancer Epidemiol Biomarkers Prev, 3, 413

Sorted by citations

Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation
Zanger, U. M., & Schwab, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.12.007 · Cited by 4,169
Polymorphism of human cytochrome P450 enzymes and its clinical impact
Zhou, S., Liu, J., & Chowbay, B. (2009) · Drug Metabolism Reviews · doi:10.1080/03602530902843483 · Cited by 857
International society of sports nutrition position stand: caffeine and performance
Goldstein, E. R., Ziegenfuss, T., Kalman, D., Kreider, R., Campbell, B., Wilborn, C., Taylor, L., Willoughby, D., Stout, J., Graves, B. S., et al. (2010) · Journal of the International Society of Sports Nutrition · doi:10.1186/1550-2783-7-5 · Cited by 686
International Society of Sports Nutrition Position Stand: Caffeine and Exercise Performance
Guest, N. S., VanDusseldorp, T. A., Nelson, M. T., Grgic, J., Schoenfeld, B. J., Jenkins, N. D. M., Arent, S. M., Antonio, J., Stout, J. R., Trexler, E. T., et al. (2021) · Journal of the International Society of Sports Nutrition · doi:10.1186/s12970-020-00383-4 · Cited by 665
Interindividual Differences in Caffeine Metabolism and Factors Driving Caffeine Consumption
Nehlig, A. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014407 · Cited by 632
Scientific Opinion on the safety of caffeine
EFSA Panel on Dietetic Products, N. A. A. (. (2015) · EFSA Journal · doi:10.2903/j.efsa.2015.4102 · Cited by 613
Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation
Zanger, U. M., Turpeinen, M., Klein, K., & Schwab, M. G. (2008) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-008-2291-6 · Cited by 593
Cytochrome P450 pharmacogenetics and cancer
Rodríguez‐Antona, C., & Ingelman‐Sundberg, M. (2006) · Oncogene · doi:10.1038/sj.onc.1209377 · Cited by 574
Inhibition and induction of human cytochrome P450 enzymes: current status
Pelkonen, O., Turpeinen, M., Hakkola, J., Honkakoski, P., Hukkanen, J., & Raunio, H. (2008) · Archives of Toxicology · doi:10.1007/s00204-008-0332-8 · Cited by 571
Coffee, CYP1A2 genotype, and risk of myocardial infarction
Cornelis, M. C., El-Sohemy, A., Kabagambe, E. K., & Campos, H. (2006) · JAMA · doi:10.1001/jama.295.10.1135 · Cited by 490
The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes
Parkinson, A. (2004) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2004.01.010 · Cited by 385
Caffeine Use in Sports, Pharmacokinetics in Man, and Cellular Mechanisms of Action
Magkos, F., & Kavouras, S. A. (2005) · Critical Reviews in Food Science and Nutrition · doi:10.1080/1040-830491379245 · Cited by 367
Genetics of caffeine consumption and responses to caffeine
Yang, A., Palmer, A. A., & de Wit, H. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1900-1 · Cited by 330
The clinical toxicology of caffeine: A review and case study
Willson, C. (2018) · Toxicology Reports · doi:10.1016/j.toxrep.2018.11.002 · Cited by 289
Assessment of CYP1A2 Activity in Clinical Practice: Why, How, and When?
Faber, M. S., Jetter, A., & Fuhr, U. (2005) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2005.pto_973160.x · Cited by 284
A genetic variation in the adenosine A2A receptor gene (ADORA2A) contributes to individual sensitivity to caffeine effects on sleep
Rétey, J. V., Adam, M., Khatami, R., Luhmann, U. F. O., Jung, H. H., Berger, W., & Landolt, H.-P. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100102 · Cited by 278
Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans
Ghotbi, R., Christensen, M., Roh, H., Ingelman‐Sundberg, M., Aklillu, E., & Bertilsson, L. (2007) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-007-0288-2 · Cited by 265
Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2
Zhou, S.-F., Wang, B., Yang, L.-P., & Liu, J. (2009) · Drug Metabolism Reviews · doi:10.3109/03602530903286476 · Cited by 270
Pharmacokinetics and metabolism of natural methylxanthines in animal and man
Arnaud, M. J. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-13443-2_3 · Cited by 259
Variation in CYP1A2 Activity and its Clinical Implications: Influence of Environmental Factors and Genetic Polymorphisms
Gunes, A., & Dahl, M. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.5.625 · Cited by 257
Neuroprotective Effects of Coffee Bioactive Compounds: A Review
Socała, K., Szopa, A., Serefko, A., Poleszak, E., & Właź, P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010107 · Cited by 271
Insights into the Substrate Specificity, Inhibitors, Regulation, and Polymorphisms and the Clinical Impact of Human Cytochrome P450 1A2
Zhou, S. F., Yang, L.-P., Zhou, Z.-W., Liu, Y., & Chan, E. (2009) · The AAPS Journal · doi:10.1208/s12248-009-9127-y · Cited by 239
Genetic polymorphism of the adenosine A2A receptor is associated with habitual caffeine consumption
Cornelis, M. C., El‐Sohemy, A., & Campos, H. (2007) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/86.1.240 · Cited by 231
CYP1A2 genotype modifies the association between coffee intake and the risk of hypertension
Palatini, P., Ceolotto, G., Ragazzo, F., Dorigatti, F., Saladini, F., Papparella, I., Mos, L., Zanata, G., & Santonastaso, M. (2009) · Journal of Hypertension · doi:10.1097/hjh.0b013e32832ba850 · Cited by 230
Caffeine Consumption through Coffee: Content in the Beverage, Metabolism, Health Benefits and Risks
DePaula, J., & Farah, A. (2019) · Beverages · doi:10.3390/beverages5020037 · Cited by 258
Human Cytochrome P450 Enzymes
Guengerich, F. P. (2007) · Springer eBooks · doi:10.1007/0-387-27447-2_10 · Cited by 226
Genetic Polymorphism of CYP1A2 in Ethiopians Affecting Induction and Expression: Characterization of Novel Haplotypes with Single-Nucleotide Polymorphisms in Intron 1
Aklillu, E., Carrillo, J. A., Makonnen, E., Hellman, K., Pitarque, M., Bertilsson, L., & Ingelman‐Sundberg, M. (2003) · Molecular Pharmacology · doi:10.1124/mol.64.3.659 · Cited by 181
Pharmacogenetics of Drug Metabolism
Flockhart, D. A., & Desta, Z. (2009) · Elsevier eBooks · doi:10.1016/b978-0-12-373639-0.00021-2 · Cited by 151
Human Cytochrome P450 Enzymes
Guengerich, F. P. (2015) · Springer eBooks · doi:10.1007/978-3-319-12108-6_9 · Cited by 159
PharmGKB summary
Thorn, C. F., Aklillu, E., Klein, T. E., & Altman, R. B. (2011) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32834c6efd · Cited by 141
Genome-wide association analysis of coffee drinking suggests association with CYP1A1/CYP1A2 and NRCAM
kConFab Investigators, Amin, N., Byrne, E. M., Johnson, J., Chenevix‐Trench, G., Walter, S., Nolte, I. M., Vink, J. M., Rawal, R., Mangino, M., et al. (2011) · Molecular Psychiatry · doi:10.1038/mp.2011.101 · Cited by 139
What Should We Do about Habitual Caffeine Use in Athletes?
Pickering, C., & Kiely, J. (2019) · Sports Medicine · doi:10.1007/s40279-018-0980-7 · Cited by 127
Precision (Personalized) Nutrition: Understanding Metabolic Heterogeneity
Zeisel, S. H. (2020) · Annual Review of Food Science and Technology · doi:10.1146/annurev-food-032519-051736 · Cited by 135
Long-term coffee consumption, caffeine metabolism genetics, and risk of cardiovascular disease: a prospective analysis of up to 347,077 individuals and 8368 cases
Zhou, A., & Hyppönen, E. (2018) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqy297 · Cited by 125
Oral contraceptives containing ethinyl estradiol and gestodene markedly increase plasma concentrations and effects of tizanidine by inhibiting cytochrome P450 1A2
Granfors, M. T., Backman, J. T., Laitila, J., & Neuvonen, P. J. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.06.009 · Cited by 113
Update Information on Drug Metabolism Systems— 2009, Part II. Summary of Information on the Effects of Diseases and Environmental Factors on Human Cytochrome P450 (CYP) Enzymes and Transporters
Rendić, S., & Guengerich, F. P. (2010) · Current Drug Metabolism · doi:10.2174/138920010791110917 · Cited by 111
Pharmacokinetics of Caffeine: A Systematic Analysis of Reported Data for Application in Metabolic Phenotyping and Liver Function Testing
Grzegorzewski, J., Bartsch, F., Köller, A., & König, M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.752826 · Cited by 108
“A large heritability of CYP1A2 activity could be shown by a twin study (Rasmussen et al., 2002).”
Background
The impact of genetic polymorphisms on CYP1A2 activity in humans: a systematic review and meta-analysis
Koonrungsesomboon, N., Khatsri, R., Wongchompoo, P., & Teekachunhatean, S. (2018) · The Pharmacogenomics Journal · doi:10.1038/s41397-017-0011-3 · Cited by 100
Pathway-Targeted Pharmacogenomics of CYP1A2 in Human Liver
Klein, K., Winter, S., Turpeinen, M., Schwab, M. G., & Zanger, U. M. (2010) · Frontiers in Pharmacology · doi:10.3389/fphar.2010.00129 · Cited by 96
The Acute Effects of Caffeinated Black Coffee on Cognition and Mood in Healthy Young and Older Adults
Haskell‐Ramsay, C. F., Jackson, P. A., Forster, J. S., Dodd, F. L., Bowerbank, S. L., & Kennedy, D. O. (2018) · Nutrients · doi:10.3390/nu10101386 · Cited by 104
Measurement of CYP1A2 Activity: A Focus on Caffeine as a Probe
Perera, V., Gross, A. S., & McLachlan, A. J. (2012) · Current Drug Metabolism · doi:10.2174/1389200211209050667 · Cited by 92
Some Aspects of Genetic Polymorphism in the Biotransformation of Antidepressants
Brøsen, K. (2004) · Therapies · doi:10.2515/therapie:2004003 · Cited by 92
Pharmacogenetics and outcome with antipsychotic drugs
Pouget, J. G., Shams, T. A., Tiwari, A. K., & Müller, D. J. (2014) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2014.16.4/jpouget · Cited by 91
Modulation of CYP 450 Activities in Patients With Type 2 Diabetes
Gravel, S., Chiasson, J., Turgeon, J., Grangeon, A., & Michaud, V. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1496 · Cited by 84
Effects of caffeine intake on the pharmacokinetics of melatonin, a probe drug for CYP1A2 activity
Härtter, S., Nordmark, A., Rose, D., Bertilsson, L., Tybring, G., & Laine, K. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01933.x · Cited by 79
Single Nucleotide Polymorphisms and Haplotypes of CYP1A2 in a Japanese Population
Soyama, A., Saito, Y., Hanioka, N., Maekawa, K., Komamura, K., Kamakura, S., Kitakaze, M., Tomoike, H., Ueno, K., Goto, Y., et al. (2005) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.20.24 · Cited by 79
Prediction of drug response and adverse drug reactions: From twin studies to Next Generation Sequencing
Lauschke, V. M., & Ingelman‐Sundberg, M. (2019) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2019.01.024 · Cited by 79
Heritability of metoprolol and torsemide pharmacokinetics
Matthaei, J., Brockmöller, J., Tzvetkov, M. V., Sehrt, D. B., Sachse-Seeboth, C., Hjelmborg, J., Möller, S., Halekoh, U., Hofmann, U., Schwab, M. G., et al. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.258 · Cited by 75
Influence of Genetic Polymorphisms, Smoking, Gender And Age on Cyp1A2 Activity in a Turkish Population
Gunes, A., Özbey, G., Vural, E. H., Uluoğlu, C., Scordo, M. G., Zengil, H., & Dahl, M. (2009) · Pharmacogenomics · doi:10.2217/pgs.09.22 · Cited by 74
Drug metabolism and drug transport of the 100 most prescribed oral drugs
Iversen, D. B., Andersen, N. E., Dunvald, A. D., Pottegård, A., & Stage, T. B. (2022) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13780 · Cited by 72
Functional characterization of four allelic variants of human cytochrome P450 1A2
Zhou, H., Josephy, P. D., Kim, D., & Guengerich, F. P. (2003) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2003.11.019 · Cited by 73
Drug–Drug Interactions Involving Intestinal and Hepatic CYP1A Enzymes
Klomp, F., Wenzel, C., Droździk, M., & Oswald, S. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12121201 · Cited by 70
Genetic determinants of blood pressure responses to caffeine drinking
Renda, G., Zimarino, M., Antonucci, I., Tatasciore, A., Ruggieri, B., Bucciarelli, T., Prontera, T., Stuppia, L., & Caterina, R. D. (2011) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.111.018267 · Cited by 69
Population-based case–control study of AhR (aryl hydrocarbon receptor) and CYP1A2 polymorphisms and breast cancer risk
Long, J., Egan, K. M., Dunning, L., Shu, X., Cai, Q., Cai, H., Dai, Q., Holtzman, J. L., Gao, Y.-T., & Zheng, W. (2006) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000189803.34339.ed · Cited by 66
Maternal Smoking and Fetal Sex Significantly Affect Metabolic Enzyme Expression in the Human Fetal Liver
O’Shaughnessy, P. J., Monteiro, A., Bhattacharya, S., & Fowler, P. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1437 · Cited by 70
PhRMA White Paper on ADME Pharmacogenomics
Williams, J. A., Andersson, T., Andersson, T. B., Blanchard, R. L., Behm, M. O., Cohen, N., Edeki, T. I., Franc, M. A., Hillgren, K. M., Johnson, K. J., et al. (2008) · The Journal of Clinical Pharmacology · doi:10.1177/0091270008319329 · Cited by 65
Meat Intake, Heterocyclic Amine Exposure, and Metabolizing Enzyme Polymorphisms in Relation to Colorectal Polyp Risk
Shin, A., Shrubsole, M. J., Rice, J. M., Cai, Q., Doll, M. A., Long, J., Smalley, W. E., Shyr, Y., Sinha, R. R., Ness, R. M., et al. (2008) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-07-0615 · Cited by 64
Caffeine Intake During Pregnancy and Risk of Problem Behavior in 5- to 6-Year-Old Children
Loomans, E. M., Hofland, L., van der Stelt, O., van der Wal, M. F., Koot, H. M., den Bergh, B. R. H. V., & Vrijkotte, T. G. M. (2012) · PEDIATRICS · doi:10.1542/peds.2011-3361 · Cited by 64
The G−113A polymorphism in affects the caffeine metabolic ratio in a Chinese population
Chen, X., WANG, L., ZHI, L., Zhou, G.-D., WANG, H., ZHANG, X., Hao, B., Zhu, Y., Cheng, Z., & HE, F. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.05.012 · Cited by 63
Pharmacogenetics of Drug Metabolism
Desta, Z., & Flockhart, D. A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802101-9.00018-1 · Cited by 62
Maternal caffeine intake during pregnancy and risk of fetal growth restriction: a large prospective observational study
Konje, J. C. (2010) · BMJ · doi:10.1136/bmj.c2331 · Cited by 59
Genetic determinants in the metabolism of bladder carcinogens in relation to risk of bladder cancer
Yuan, J., Chan, K. K. L., Coetzee, G. A., Castelao, J. E., Watson, M. A., Bell, D. A., Wang, R., & Yu, M. C. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn136 · Cited by 59
Modulation of the growth hormone–insulin-like growth factor (GH–IGF) axis by pharmaceutical, nutraceutical and environmental xenobiotics: An emerging role for xenobiotic-metabolizing enzymes and the transcription factors regulating their expression. A review
Scarth, J. P. (2006) · Xenobiotica · doi:10.1080/00498250600621627 · Cited by 58
More than just caffeine: psychopharmacology of methylxanthine interactions with plant-derived phytochemicals
Schuster, J., & Mitchell, E. S. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.09.005 · Cited by 60
Pharmacogenetic tests for antipsychotic medications: clinical implications and considerations
Eum, S., Lee, A. M., & Bishop, J. R. (2016) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2016.18.3/jbishop · Cited by 55
Genetic susceptibility to caffeine intake and metabolism: a systematic review
Low, J. J.-L., Tan, B. J., Yi, L., Zhou, Z., & Tan, E. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05737-z · Cited by 70
Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study
Hong, C., Tang, B.-K., Hammond, G. L., Tritchler, D., Yaffe, M. J., & Boyd, N. F. (2004) · Breast Cancer Research · doi:10.1186/bcr798 · Cited by 54
Extractionless method for the determination of urinary caffeine metabolites using high-performance liquid chromatography coupled with tandem mass spectrometry
Schneider, H., Ma, L., & Glatt, H. R. (2003) · Journal of Chromatography B · doi:10.1016/s1570-0232(03)00065-5 · Cited by 53
Reduced Neurobehavioral Impairment from Sleep Deprivation in Older Adults: Contribution of Adenosinergic Mechanisms
Landolt, H., Rétey, J., & Adam, M. (2012) · Frontiers in Neurology · doi:10.3389/fneur.2012.00062 · Cited by 55
Theophylline: a review of population pharmacokinetic analyses
J., Y., Jiang, D. Q., Meng, J. X., Li, M. X., Zhao, H., Wang, Y., & Wang, L. Q. (2016) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12435 · Cited by 51
Sleep Pharmacogenetics: Personalized Sleep-Wake Therapy
Holst, S. C., Valomon, A., & Landolt, H. (2015) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010715-103801 · Cited by 48
Coffee Consumption and CYP1A2*1F Genotype Modify Age at Breast Cancer Diagnosis and Estrogen Receptor Status
Bågeman, E., Ingvar, C., Rose, C., & Jernström, H. (2008) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-07-0555 · Cited by 48
In vitroInhibition of CYP1A2 by Model Inhibitors, Anti‐Inflammatory Analgesics and Female Sex Steroids: Predictability ofin vivoInteractions
Karjalainen, M. J., Neuvonen, P. J., & Backman, J. T. (2008) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2008.00252.x · Cited by 47
Role of Xenobiotic Metabolic Enzymes in Cancer Epidemiology
Singh, M. S., & Michael, M. (2008) · Methods in molecular biology · doi:10.1007/978-1-60327-492-0_10 · Cited by 46
Effects of gender and moderate smoking on the pharmacokinetics and effects of the CYP1A2 substrate tizanidine
Backman, J. T., Schröder, M. T., & Neuvonen, P. J. (2007) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-007-0389-y · Cited by 45
Common questions and misconceptions about caffeine supplementation: what does the scientific evidence really show?
António, J., Newmire, D. E., Stout, J. R., Antonio, B. B., Gibbons, M., Lowery, L. M., Harper, J., Willoughby, D. S., Evans, C., Anderson, D., et al. (2024) · Journal of the International Society of Sports Nutrition · doi:10.1080/15502783.2024.2323919 · Cited by 57
To Genotype or Phenotype for Personalized Medicine? CYP450 Drug Metabolizing Enzyme Genotype–Phenotype Concordance and Discordance in the Ecuadorian Population
de Andrés, F., Terán, S., Hernández, F., Terán, E., & LLerena, A. (2016) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2016.0148 · Cited by 44
Impact of Foods and Dietary Supplements Containing Hydroxycinnamic Acids on Cardiometabolic Biomarkers: A Systematic Review to Explore Inter-Individual Variability
Martini, D., Chiavaroli, L., González‐Sarrías, A., Bresciani, L., Palma-Duran, S. A., Dall’Asta, M., Deligiannidou, G.-E., Massaro, M., Scoditti, E., Combet, E., et al. (2019) · Nutrients · doi:10.3390/nu11081805 · Cited by 43
Pharmacogenomics of anticoagulants: steps toward personal dosage
Daly, A. K. (2009) · Genome Medicine · doi:10.1186/gm10 · Cited by 44
Gender Differences in Any-Source Caffeine and Energy Drink Use and Associated Adverse Health Behaviors
Dillon, P. M., Kelpin, S. S., Kendler, K. S., Thacker, L. R., Dick, D. M., & Svikis, D. S. (2019) · Journal of Caffeine and Adenosine Research · doi:10.1089/caff.2018.0008 · Cited by 48
Phenotype-genotype analysis of CYP1A2 in Japanese patients receiving oral theophylline therapy
Takata, K., Saruwatari, J., Nakada, N., Nakagawa, M., Fukuda, K., Tanaka, F., Takenaka, S., 修一, 三., Marubayashi, T., & Nakagawa, K. (2005) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-005-0057-z · Cited by 41
Where Failure Is Not an Option –Personalized Medicine in Astronauts
Stingl, J., Welker, S., Hartmann, G., Damann, V., & Gerzer, R. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140764 · Cited by 41
Considering CYP1A2 phenotype and genotype for optimizing the dose of olanzapine in the management of schizophrenia
Perera, V., Gross, A. S., Polasek, T. M., Yan, Q., Rao, G. G., Forrest, A., Xu, J., & McLachlan, A. J. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.795540 · Cited by 39
Prediction of Interindividual Variability in Pharmacokinetics for CYP3A4 Substrates in Humans
Kato, M., Chiba, K., Ito, T., Koue, T., & Sugiyama, Y. (2010) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-09-rg-038 · Cited by 38
Heritability of Caffeine Metabolism: Environmental Effects Masking Genetic Effects on CYP1A2 Activity but Not on NAT2
Matthaei, J., Tzvetkov, M. V., Strube, J., Sehrt, D. B., Sachse-Seeboth, C., Hjelmborg, J., Möller, S., Halekoh, U., Hofmann, U., Schwab, M. G., et al. (2016) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.444 · Cited by 38
Effect of Cytochrome P450 polymorphism on the action and metabolism of selective serotonin reuptake inhibitors
Probst-Schendzielorz, K., Viviani, R., & Stingl, J. (2015) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2015.1052791 · Cited by 37
Factors affecting interindividual differences in clozapine response: a review and case report
Bersani, F. S., Capra, E., Minichino, A., Pannese, R., Girardi, N., Marini, I., Chiaie, R. D., & Biondi, M. (2011) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1191 · Cited by 37
A Conceptual Framework for Studying and Investing in Precision Nutrition
Zeisel, S. H. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00200 · Cited by 37
Gender and body mass index modify the effect of increasing amounts of caffeinated coffee on postprandial glucose and insulin concentrations; a randomized, controlled, clinical trial
Gavrieli, A., Fragopoulou, E., Mantzoros, C. S., & Yannakoulia, M. (2013) · Metabolism · doi:10.1016/j.metabol.2013.02.003 · Cited by 36
Biological sex differences in pharmacokinetics and adverse drug reactions
Aljohmani, A., & Yildiz, D. (2026) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-025-04721-8 · Cited by 35
Caffeine, selected metabolic gene variants, and risk for neural tube defects
Schmidt, R. J., Romitti, P. A., Burns, T. L., Murray, J. C., Browne, M. L., Druschel, C. M., & Olney, R. S. (2010) · Birth Defects Research Part A Clinical and Molecular Teratology · doi:10.1002/bdra.20681 · Cited by 35
FUNCTIONAL ANALYSIS OF THREE CYP1A2 VARIANTS FOUND IN A JAPANESE POPULATION
Saito, Y., Hanioka, N., Maekawa, K., Isobe, T., Tsuneto, Y., Nakamura, R., Soyama, A., Ozawa, S., Tanaka-Kagawa, T., Jinno, H., et al. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.005819 · Cited by 34
Association of Coffee and Caffeine Intake With Irritable Bowel Syndrome in Adults
Koochakpoor, G., Salari-Moghaddam, A., Keshteli, A. H., Esmaillzadeh, A., & Adibi, P. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.632469 · Cited by 33
Stillbirth and slow metabolizers of caffeine: comparison by genotypes
Bech, B. H., Autrup, H. N., Nohr, E. A., Henriksen, T. B., & Olsen, J. (2006) · International Journal of Epidemiology · doi:10.1093/ije/dyl116 · Cited by 33
Current status on genome–metabolome-wide associations: an opportunity in nutrition research
Montoliu, I., Genick, U. K., Ledda, M., Collino, S., Martin, F., le Coutre, J., & Rezzi, S. (2012) · Genes & Nutrition · doi:10.1007/s12263-012-0313-7 · Cited by 31
Protective Effect of Caffeine and Chlorogenic Acids of Coffee in Liver Disease
Pietrantonio, D. D., Palitti, V. P., Cichelli, A., & Tacconelli, S. (2024) · Foods · doi:10.3390/foods13142280 · Cited by 31
Comparison of CYP1A2 and NAT2 phenotypes between black and white smokers
Muscat, J. E., Pittman, B. P., Kleinman, W. A., Lazarus, P. J., Stellman, S. D., & Richie, J. P. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.07.024 · Cited by 31
Multigenic Control of Drug Response and Regulatory Decision-Making in Pharmacogenomics: The Need for an Upper-Bound Estimate of Genetic Contributions
Özdemir, V., KALOW, W., Tóthfalusi, L., Bertilsson, L., Endrényi, L., & Graham, J. (2005) · Current Pharmacogenomics · doi:10.2174/1570160053175027 · Cited by 30
Caffeine N3-demethylation (CYP1A2) in a population with an increased exposure to polychlorinated biphenyls
Petersen, M. S., Halling, J., Damkier, P., Nielsen, F., Grandjean, P., Weihe, P., & Brøsen, K. (2006) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-006-0205-0 · Cited by 29
The CYP1A2 –163C>A polymorphism is associated with clozapine-induced generalized tonic-clonic seizures in Brazilian schizophrenia patients
Kohlrausch, F. B., Gama, C. S., Lobato, M. I. R., Belmonte-de-Abreu, P. S., Carracedo, Á., & Hutz, M. H. (2013) · Psychiatry Research · doi:10.1016/j.psychres.2013.02.030 · Cited by 28

Authors: Rasmussen
Venue: Pharmacogenetics
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2002-08-01
Volume: 12
Issue: 6
Pages: 473-478
ISSN: 0960-314X (ISSN-L)
DOI: 10.1097/00008571-200208000-00008
OpenAlex: W237900477
Cited by: 241
References: 43
Citations by year: 2026: 9 · 2025: 13 · 2024: 8 · 2023: 7 · 2022: 11 · 2021: 8 · 2020: 6 · 2019: 12 · 2018: 11 · 2017: 6 · 2016: 10 · 2015: 9 · 2014: 10 · 2013: 12 · 2012: 13
FWCI: 5.89
Type: journal article
Language: en
Open access: closed
Locations: Pharmacogenetics (publishedVersion)
PubMed (publishedVersion)
University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion)
Topics: Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
Health Sciences › Medicine › Pharmacology (medical) › Coffee research and impacts
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
Keywords: caffeine metabolism, CYP1A2, heritability, monozygotic twins, dizygotic twins, smoking, oral contraceptives, sex differences, genetic and environmental factors
MeSH terms: Adolescent, Adult, Central Nervous System Stimulants, Biotransformation, Caffeine, Chromatography, High Pressure Liquid, Contraceptives, Oral, Hormonal, Female, Humans, Male, Middle Aged, Sex Factors, Smoking, Twins, Dizygotic, Twins, Monozygotic, Cytochrome P-450 CYP1A2, Genetic Predisposition to Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The interindividual differences in the 3‐demthylation of caffeine alias CYP1A2 is determined by both genetic and environmental factors

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks